Bayer receives approval for Eylea ® in China (for specialized target groups only)

Eylea ® gains approval in China for the treatment of visual impairment due to neovascular (wet) age-related macular degeneration
Source: Bayer Company News - Category: Pharmaceuticals Source Type: news